Trial · NCT00624416
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
NCT00624416, Phase 1, Phase 2, Completed, Pennington Biomedical Research Center; results first posted 2012-06-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas. Trials, record NCT00624416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00624416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
- NCT number
- NCT00624416
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Pennington Biomedical Research Center
- Conditions
- Lipoma
- Interventions
- Prednisolone synthetic cortisone and Isoproterenol together
- First posted
- 2008-02-27
- Last updated
- 2015-12-21
- Results first posted
- 2012-06-22
- Limitations and caveats
- The single case that did not have an increase in lipoma volume showed variability which may have been because of a small lipoma making accurate measurement difficult.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Average Percent Volume Reduction in the Lipoma. | Baseline and 4 weeks | |
| Secondary | The Number of Lipoma Increased in Volume. | After four weeks of treatment up to one year. | |
| Secondary | The Number of Subjects Elected to Have the Lipoma Removed. | After four weeks up to one year. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Average Percent Volume Reduction in the Lipoma. | Baseline and 4 weeks | Percent Volume reduction (cc^3) | MEAN | |
| SECONDARY | The Number of Lipoma Increased in Volume. | After four weeks of treatment up to one year. | Lipomas | NUMBER | |
| SECONDARY | The Number of Subjects Elected to Have the Lipoma Removed. | After four weeks up to one year. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Average Percent Volume Reduction in the Lipoma. | Prednisolone and Isoproteronol | 50 | Full Range 0.002 | Percent Volume reduction (cc^3) | |
| The Number of Lipoma Increased in Volume. | Prednisolone and Isoproteronol | 9 | Lipomas | ||
| The Number of Subjects Elected to Have the Lipoma Removed. | Prednisolone and Isoproteronol | 8 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prednisolone and Isoproteronol | 10 | |
| Overall Study | COMPLETED | Prednisolone and Isoproteronol | 10 | |
| Overall Study | NOT COMPLETED | Prednisolone and Isoproteronol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prednisolone and Isoproteronol | ||
| Total, other adverse events | Prednisolone and Isoproteronol | 0 | 10 |
| Total, serious adverse events | Prednisolone and Isoproteronol | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00624416
GET https://conductscience.org/api/trials/v1/NCT00624416/registered